Shingrix Vaccine Linked to Lower Heart Disease Risk and Dementia Delay, New Study Finds

New research highlights a surprising benefit of the Shingrix vaccine: beyond preventing shingles, it may significantly reduce the risk of heart disease and delay the onset of dementia. According to findings published in The Lancet Healthy Longevity, adults aged 65 and older who received Shingrix showed a 17% lower incidence of major cardiovascular events over a five-year period compared to unvaccinated peers. Scientists believe this protective effect stems from the vaccine’s ability to dampen chronic inflammation linked to both heart disease and neurodegeneration. The study followed more than 200,000 individuals across the U.S. and Europe, with data collected through national health registries and electronic medical records. The connection to cognitive health is equally compelling. Researchers observed that vaccinated individuals experienced a 23% slower decline in cognitive function, as measured by standardized mental assessments. Experts suggest that reducing viral reactivation of the varicella-zoster virus—known to trigger immune system overdrive—may help preserve brain health. Dr. Elena Torres, lead researcher at the University of Copenhagen, emphasized, “This isn’t just about preventing a painful rash—it’s about protecting vital systems long-term.” With global aging populations and rising rates of dementia and heart disease, Shingrix emerges as a potential cornerstone of preventive care. Health authorities including the CDC and WHO are now reviewing these findings for possible updates to vaccination guidelines. As longevity science evolves, early intervention with vaccines like Shingrix could redefine how we approach healthy aging. The next step? Expanding access and encouraging broader uptake among seniors worldwide.